8.

Cancers attributable to overweight and obesity in the UK in 2010

DM Parkin^{*,1} and L Boyd²¹Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK;²Statistical Information Team, Cancer Research UK, Angel Building, 407 St John Street, London EC1V 4AD, UK

British Journal of Cancer (2011) 105, S34–S37; doi:10.1038/bjc.2011.481 www.bjcancer.com

© 2011 Cancer Research UK

In 2002, the International Agency for Research on Cancer Handbook on Weight Control and Physical Activity concluded that overweight and obesity are related to cancers of the colon, endometrium, kidney and oesophagus (adenocarcinomas), as well as postmenopausal breast cancer. Since that report, continuing epidemiological investigation has suggested that other cancers are related to obesity and overweight. In addition to those listed above, the report by the World Cancer Research Fund (WCRF) Panel on Food, Nutrition, Physical Activity, and the Prevention of Cancer (WCRF, 2007) considered that there was convincing evidence for an association with cancers of the pancreas and rectum (as well as colon), and a probable association with cancers of the gall bladder. The fraction of these cancers occurring in 2010 attributable to overweight and obesity in the UK population is estimated in this section.

METHODS

The estimates of risk associated with overweight (BMI $25 < 30 \text{ kg m}^{-2}$) and obesity (BMI $30 + \text{kg m}^{-2}$), relative to a BMI $\leq 25 \text{ kg m}^{-2}$, for the seven cancers, are shown in Table 1. The estimates of relative risk for an increase of 5 kg m^{-2} from the meta-analyses by WCRF (2007) have been used for the category 'overweight'. Assuming a constant rate of increase in risk with BMI, the square of this value was taken for the category 'obese'. For postmenopausal breast cancer, WCRF reported that the increase in risk was 8% per BMI increase of 5 kg m^{-2} for cohort studies (17 considered) and 13% per BMI increase of 5 kg m^{-2} for case-control studies (48 considered). The estimates from the meta-analyses of Bergstrom *et al* (2001) and Renehan *et al* (2008) were almost identical (12% per BMI increase of 5 kg m^{-2}), and thus this value has been selected.

The latent period, or interval between 'exposure' to overweight/obesity and the appropriate increase in risk of these cancers, is not known. Renehan *et al* (2008) calculated the geometric mean duration of follow-up in the cohort studies available for a meta-analysis of relative risks due to overweight and obesity. The periods ranged from 8.4 years (for breast cancer) to 12.7 years (for gall bladder cancer). We therefore chose to assume that the latency

between 'exposure' and outcome would be, on average, 10 years, and thus examine the effects on cancers occurring in 2010 from suboptimal levels of body mass in 2000. The proportion of adults in the age group of 19–64 who were overweight or obese in Great Britain in 2000–2001 is available from the National Diet and Nutrition Survey (FSA, 2004; Table 4.1). For older adults (aged ≥ 65), we used the values for 2000 from the Health Survey for England (Health and Social Care Information Centre, 2010). The results are shown in Table 2.

Table 1 Relative risks associated with overweight and obesity

Cancer (site)	Relative risks		Excess relative risks	
	Overweight	Obese	Overweight	Obese
Breast (post-menopausal) ^{a,b}	1.12	1.25	0.12	0.25
Colorectum ^c	1.15	1.32	0.15	0.32
Oesophagus (adenocarcinoma) ^c	1.55	2.40	0.55	1.40
Kidney ^c	1.31	1.72	0.31	0.72
Endometrium ^c	1.52	2.31	0.52	1.31
Gall bladder ^c	1.23	1.51	0.23	0.51
Pancreas ^c	1.14	1.30	0.14	0.30

^aFrom Bergstrom *et al* (2001). ^bFrom Renehan *et al* (2008). ^cFrom WCRF (2007).

Table 2 Prevalence of overweight and obesity in Great Britain in 2000–2001

BMI	Prevalence of overweight and obesity by age group (years)					
	19–24 ^a	25–34 ^a	35–49 ^a	50–64 ^a	65–74 ^b	≥ 75 ^b
Men						
25 < 30 (overweight)	0.25	0.42	0.45	0.46	0.50	0.52
≥ 30 (obese)	0.18	0.18	0.25	0.32	0.24	0.17
Women						
25 < 30 (overweight)	0.25	0.28	0.31	0.41	0.41	0.41
≥ 30 (obese)	0.14	0.16	0.23	0.22	0.30	0.23

Abbreviations: BMI = body mass index. ^aFrom the National Diet and Nutrition Survey (ages 19–64). ^bFrom Health Survey for England (ages > 65).

*Correspondence: Professor DM Parkin; E-mail: d.m.parkin@qmul.ac.uk

Table 3 Cancer cases diagnosed in 2010 attributable to overweight and obesity in 2000

Cases attributable to obesity for each cancer																	
Proportion overweight or obese in 2000		Oesophagus (adenocarcinoma) ^{a,b}		Gallbladder		Pancreas		Colon-rectum		Breast		Corpus uteri		Kidney			
Age (years)	At outcome (+10 years)	Overweight	Obese	PAF	Obs.	Excess attributable cases	PAF	Obs.	Excess attributable cases	PAF	Obs.	Excess attributable cases	PAF	Obs.	Excess attributable cases		
Men																	
19–24	25–34	0.25	0.18	0.28	4	1	0.13	0	0.0	0.08	9	0.7	0.09	133	11.6	0.17	31
24–34	35–44	0.42	0.18	0.33	27	9	0.16	1	0.2	0.10	67	6.8	0.11	397	42.9	0.21	206
35–49	45–59	0.45	0.25	0.37	358	134	0.19	24	4.5	0.12	587	71.1	0.13	2921	376.9	0.24	1142
50–64	60–74	0.46	0.32	0.41	1405	579	0.21	83	17.6	0.14	1771	244.6	0.15	9481	1392.8	0.27	2368
65–74	75–84	0.50	0.24	0.38	963	589	0.19	59	11.5	0.13	1188	149.2	0.13	6774	905.6	0.25	1418
≥75	≥85	0.52	0.17	0.34	371	227	0.17	22	3.8	0.11	460	50.6	0.12	2388	279.7	0.22	472
Total (%)		—	—	—	5713	1538 (26.9)	—	191	37.5 (19.7)	—	4084	523.1 (12.8)	—	22 127	3009.4 (13.6)	—	5697
Women																	
19–24	25–34	0.25	0.14	0.25	1	0.2	0.11	1	0.1	0.07	11	0.8	0.08	136	10.2	0.15	29
24–34	35–44	0.28	0.16	0.27	4	1.2	0.13	8	1.0	0.08	53	4.2	0.09	402	34.4	0.17	110
35–49	45–59	0.31	0.23	0.33	50	16.5	0.16	73	11.6	0.10	437	44.1	0.11	2292	246.8	0.21	554
50–64	60–74	0.41	0.22	0.35	267	93.0	0.17	198	34.0	0.11	1520	166.9	0.12	6116	715.3	0.22	1275
65–74	75–84	0.41	0.30	0.39	320	125.9	0.20	143	28.6	0.13	1374	177.4	0.14	5527	759.3	0.26	903
≥75	≥85	0.41	0.23	0.36	220	78.5	0.18	86	15.2	0.11	884	100.2	0.12	3283	396.3	0.23	428
Total (%)		—	—	—	2819	315.3 (11.2)	—	509	90.5 (17.8)	—	4280	493.6 (11.5)	—	17 787	2162.4 (12.2)	—	3365
Persons																	
19–24	25–34	—	—	—	0	1.2	—	1	0.1	—	20	1.5	—	269	21.8	—	60
24–34	35–44	—	—	—	31	10.0	—	9	1.2	—	120	11.0	—	799	77.3	—	316
35–49	45–59	—	—	—	408	150.4	—	97	16.1	—	1024	115.3	—	5213	623.7	—	1696
50–64	60–74	—	—	—	1672	672.4	—	281	51.6	—	3291	411.5	—	15 597	2108.1	—	3844
65–74	75–84	—	—	—	1283	714.4	—	202	40.0	—	2562	326.6	—	12 301	1664.9	—	1570
≥75	≥85	—	—	—	591	305.1	—	108	19.0	—	1344	150.8	—	5671	712.0	—	900
Total (%)		—	—	—	8532	1853 (21.7)	—	700	128 (18.3)	—	8364	1017 (12.2)	—	48 385	4367 (9.0)	—	8195

Abbreviations: Obs = observed cases; PAF = population-attributable fraction. ^aObserved cases are for adenocarcinoma only. ^bTotal observed cases (and percentages) are for all oesophageal cancers, and so are greater than the sum of observed cases.

The number of oesophageal cancers diagnosed in 2010 was partitioned by histological subtype, according to the age- and sex-specific distribution observed in the UK Cancer registries reporting to Cancer Incidence in Five Continents, Volume VIII (Parkin *et al*, 2002). These age-specific proportions were scaled to correspond to the crude proportions observed in the UK registries in 2000–2002 (Curado *et al*, 2007), when adenocarcinomas comprised 69.9% of oesophageal cancers in men and 39.9% in women.

The population-attributable fraction (PAF) was calculated for each sex–age group, corresponding to the level of overweight/obesity 10 years previously, according to the usual formula:

$$\text{PAF} = \frac{(p_1 \times \text{ERR}_1) + (p_2 \times \text{ERR}_2)}{1 + [(p_1 \times \text{ERR}_1) + (p_2 \times \text{ERR}_2)]}$$

where p_1 is the proportion of population overweight, p_2 the proportion of population obese, ERR_1 the excess relative risk ($\text{RR}-1$) for overweight and ERR_2 the excess relative risk ($\text{RR}-1$) for obesity.

RESULTS

Table 3 shows the calculation of attributable fractions, and corresponding numbers of attributable cases, by age group and sex, for seven cancer types accepted to be causally related to excess body weight, assuming a 10-year latency between the presence of excess body mass and cancer risk.

Table 4 summarises these results. An estimated 17 294 excess in cancer cases occurring in 2010 were due to overweight and obesity (5.5% of all cancers). The sites contributing most to this excess are large bowel (5172) and breast (4194).

DISCUSSION

The list of cancers that have been selected as being related to excess body mass (overweight and obesity) is a conservative one. It corresponds to those in the consensus statements of IARC (2002) and WCRF (2007). Needless to say, other studies have identified a large number of other cancers to be associated with excess body mass. In the recent meta-analysis of prospective studies (cohort studies and clinical trials) by Renehan *et al* (2008), there was a positive (statistically significant) association between BMI and cancer of the thyroid, leukaemia, malignant melanoma (men only), non-Hodgkin lymphoma and multiple myeloma. Others have reported significant associations with cancers of the prostate (Bergstrom *et al*, 2001), ovary (Reeves *et al*, 2007; Schouten *et al*, 2008; Lahmann *et al*, 2010) and brain (Benson *et al*, 2008), as well as cancers of the liver (Larsson and Wolk, 2007) and gastric cardia (Calle and Kaaks, 2004).

In common with most reviews, we have chosen to ignore possible differences in risk between men and women, although for some cancers – especially colorectal cancers – a greater effect in men than in women is found in some studies (Calle and Kaaks, 2004; Renehan *et al*, 2008) but not others (Bergstrom *et al*, 2001).

The 10-year ‘latency’ used to define the relevant time period at which to measure population prevalence of overweight and obesity is somewhat arbitrary. It was based on the average period of

Table 4 Numbers and proportion of cases occurring at selected sites attributable to overweight and obesity (UK 2010)

Cancer	Excess attributable cases (PAF)		
	Male	Female	Persons
Oesophagus	1538 (26.9)	315 (11.2)	1853 (21.7)
Gallbladder	381 (9.7)	91 (17.8)	128 (18.3)
Pancreas	523 (12.8)	494 (11.5)	1017 (12.2)
Colorectum	3009 (13.6)	2162 (12.2)	5172 (13.0)
Breast	—	4194 (8.7)	4194 (8.7)
Endometrium	—	2759 (33.7)	2759 (33.7)
Kidney	1422 (25.0)	749 (22.2)	2171 (24.0)
All cancers ^a	6530 (4.1)	10 764 (6.9)	17 294 (5.5)

Abbreviations: PAF = population-attributable fraction (%). ^aExcluding non-melanoma skin cancer.

follow-up in the large cohort studies from which the estimates of relative risk are derived (as reported by Renehan *et al*, 2008).

Several previous estimates of the fraction of cancer in the UK attributable to overweight and obesity have been published. Bergstrom *et al* (2001) considered a similar range of cancers to those in this paper, but included cancers of the prostate as related to BMI, and excluded oesophageal adenocarcinoma; based on relative risks from their own meta-analyses, they estimated that 2.7% of cancers diagnosed in men and 4.9% in women in the UK in 1995 were related to overweight/obesity during 1983–6. Renehan *et al* (2010) include a much wider range of cancers, as noted earlier, based on their meta-analysis of 2008 (Renehan *et al*, 2008); their estimate of attributable fraction (for 2002, based on overweight/obesity (single category) in 1992 (from WHO)) was 4.01% in women and 3.42% in men. Reeves *et al* (2007) used the results of the Million Women Study to estimate that 5% of cancers in postmenopausal women in 2004 were related to overweight and obesity (based on prevalence in England in the same year), and including nine cancers observed to have a significant trend of increasing risk with increasing BMI (including leukaemia, ovary, multiple myeloma and non-Hodgkin lymphoma, but excluding colorectal cancers). The estimate of the proportion of cancers related to ‘body fatness’ in the UK in 2002 by WCRF/AICR (2009) is given only for the seven sites analysed in this paper: 18% of the five cancers in men and 16% of the seven in women. This would be equivalent to an overall AF (for all cancers) of 4.2% in men and 8.7% in women. There are several reasons for this larger estimate. WCRF selected ‘representative’ studies from which to take the relative risks – almost all are in excess of the pooled values from their own meta-analyses. Exposure prevalence was taken from data for the same year as outcome (2002); exposure prevalence would have been lower if prevalence at an earlier period had been used, given the continuously rising trend of overweight and obesity in recent years. Finally, the baseline category (not overweight or obese) was not always $\leq 25 \text{ kg m}^{-2}$, but for some cancers (breast and pancreas) it was $\leq 23 \text{ kg m}^{-2}$.

See acknowledgements on page Si.

Conflict of interest

The authors declare no conflict of interest.

REFERENCES

- Benson VS, Pirie K, Green J, Casabonne D, Beral V (2008) Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *Br J Cancer* **99**: 185–190
- Bergstrom A, Pisani P, Tenet V, Wolk A, Adami H-O (2001) Overweight as an avoidable cause of cancer in Europe. *Int J Cancer* **91**: 421–430

- Calle E, Kaaks R (2004) Overweight, obesity and cancer. Epidemiological evidence and proposed mechanisms. *Nat Rev Cancer* **4**: 579–591
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) (2007) *Cancer Incidence in Five Continents* Vol. IX. IARC Scientific Publications No. 160. International Agency for Research on Cancer: Lyon

- Food Standards Agency (FSA) (2004) *National Diet and Nutrition Survey: Adults Aged 19 to 64, Vol. 5. Summary Report*. <http://www.food.gov.uk/multimedia/pdfs/ndnsprintedreport>
- Health and Social Care Information Centre (2010) *Health Survey for England – 2009: Trend tables*. <http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles-related-surveys/health-survey-for-england/health-survey-for-england-2009-trend-tables>
- International Agency for Research on Cancer (IARC) WHO (2002) *IARC Handbooks of Cancer Prevention: Weight Control and Physical Activity*, Vol. 6. International Agency for Research on Cancer: Lyon, France
- Lahmann PH, Cust AE, Friedenreich CM, Schulz M, Lukanova A, Kaaks R, Lundin E, Tjønneland A, Halkjaer J, Severinsen MT, Overvad K, Fournier A, Chabbert-Buffet N, Clavel-Chapelon F, Dossus L, Pischon T, Boeing H, Trichopoulou A, Lagiou P, Naska A, Palli D, Grioni S, Mattiello A, Tumino R, Sacerdote C, Redondo ML, Jakšzyn P, Sánchez MJ, Tormo MJ, Ardanaz E, Arriola L, Manjer J, Jirstrom K, Bueno-de-Mesquita HB, May AM, Peeters PH, Onland-Moret NC, Bingham S, Khaw KT, Allen NE, Spencer E, Rinaldi S, Slimani N, Chajes V, Michaud D, Norat T, Riboli E (2010) Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* **126**: 2404–2415
- Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. *Br J Cancer* **97**: 1005–1008
- Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds.) (2002). *Cancer Incidence in Five Continents*, Vol. VIII. IARC Scientific Publications No. 155. IARC: Lyon
- Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *Br Med J* **335**: 1134
- Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, Buchan I (2010) Incident cancer burden attributable to excess body mass index in 30 European countries. *Int J Cancer* **126**: 692–702
- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* **371**: 569–578
- Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami H-O, Arslan A, Beeson WL, van den Brandt PA, Buring JE, Folsom AR, Fraser GE, Freudenheim JL, Goldbohm RA, Hankinson SE, Lacey Jr JV, Leitzmann M, Lukanova A, Marshall JR, Miller AB, Patel AV, Rodriguez C, Rohan TE, Ross JA, Wolk A, Zhang SM, Smith-Warner SA (2008) Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. *Cancer Epidemiol Biomarkers Prev* **17**: 902–912
- World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) (2009) *Policy and Action for Cancer Prevention. Food, Nutrition and Physical Activity: A Global Perspective*. AICR: Washington, DC
- World Cancer Research Fund Panel (WCRFP) (2007) *Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective*. World Cancer Research Fund: Washington, DC

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>